Narrowing the Knowledge Gaps on the Duration of Transferred Protective Immunity and on Vaccination Frequency by Gaillard, María Emilia et al.
September 2017 | Volume 8 | Article 10991
Original research
published: 06 September 2017
doi: 10.3389/fimmu.2017.01099
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Elizabeth Whittaker, 




Walter Reed Army Institute of 
Research, United States  
Ji Wang, 
Harvard Medical School, 
United States
*Correspondence:




This article was submitted 
to Vaccines and Molecular 
Therapeutics, 






Gaillard ME, Bottero D, Zurita ME, 
Carriquiriborde F, Martin Aispuro P, 
Bartel E, Sabater-Martínez D, 
Bravo MS, Castuma C and 
Hozbor DF (2017) Pertussis Maternal 
Immunization: Narrowing the 
Knowledge Gaps 
on the Duration of Transferred 
Protective Immunity and on 
Vaccination Frequency. 
Front. Immunol. 8:1099. 
doi: 10.3389/fimmu.2017.01099
Pertussis Maternal immunization: 
narrowing the Knowledge gaps  
on the Duration of Transferred 
Protective immunity and on 
Vaccination Frequency
María Emilia Gaillard, Daniela Bottero, María Eugenia Zurita, Francisco Carriquiriborde, 
Pablo Martin Aispuro, Erika Bartel, David Sabater-Martínez, María Sol Bravo,  
Celina Castuma and Daniela Flavia Hozbor*
Laboratorio VacSal, Instituto de Biotecnología y Biología Molecular (IBBM), Facultad de Ciencias Exactas,  
Universidad Nacional de La Plata, CCT-CONICET La Plata, La Plata, Argentina
Maternal safety through pertussis vaccination and subsequent maternal–fetal-antibody 
transfer are well documented, but information on infant protection from pertussis by 
such antibodies and by subsequent vaccinations is scarce. Since mice are used exten-
sively for maternal-vaccination studies, we adopted that model to narrow those gaps 
in our understanding of maternal pertussis immunization. Accordingly, we vaccinated 
female mice with commercial acellular pertussis (aP) vaccine and measured offspring 
protection against Bordetella pertussis challenge and specific-antibody levels with or 
without revaccination. Maternal immunization protected the offspring against pertussis, 
with that immune protection transferred to the offspring lasting for several weeks, as 
evidenced by a reduction (4–5 logs, p < 0.001) in the colony-forming-units recovered 
from the lungs of 16-week-old offspring. Moreover, maternal-vaccination-acquired 
immunity from the first pregnancy still conferred protection to offspring up to the fourth 
pregnancy. Under the conditions of our experimental protocol, protection to offspring 
from the aP-induced immunity is transferred both transplacentally and through breast-
feeding. Adoptive-transfer experiments demonstrated that transferred antibodies were 
more responsible for the protection detected in offspring than transferred whole spleen 
cells. In contrast to reported findings, the protection transferred was not lost after the 
vaccination of infant mice with the same or other vaccine preparations, and conversely, 
the immunity transferred from mothers did not interfere with the protection conferred 
by infant vaccination with the same or different vaccines. These results indicated that 
aP-vaccine immunization of pregnant female mice conferred protective immunity that is 
transferred both transplacentally and via offspring breastfeeding without compromising 
the protection boostered by subsequent infant vaccination. These results—though 
admittedly not necessarily immediately extrapolatable to humans—nevertheless enabled 
us to test hypotheses under controlled conditions through detailed sampling and data 
collection. These findings will hopefully refine hypotheses that can then be validated in 
subsequent human studies.
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inTrODUcTiOn
Pertussis or whooping cough is a respiratory disease mainly 
caused by the Gram-negative coccobacillus Bordetella pertussis. 
This disease affects all individuals regardless of age, but with 
higher morbidity and mortality rates among infants that have 
received either no vaccine or an incomplete vaccination schedule 
(1–3). Pertussis has resurged as a major public health concern 
in many countries (4, 5). Until two decades ago, the control of 
the disease was mainly carried out through a vaccination scheme 
consisting in a three-dose primary series, with the first dose 
administered as early as at 6 weeks of life, with subsequent doses 
being completed by 6 months of age (6). In order to accomplish 
the three-dose primary series, two types of vaccines are currently 
available: a whole-cell vaccine based on standardized cultures of 
B. pertussis strains (wP) and an acellular form [acellular pertussis 
(aP)] composed of purified B. pertussis immunogens. Acellular 
vaccines, originally developed to reduce the side effects associ-
ated with wP vaccination (7, 8), have since replaced wP, especially 
in industrialized countries. Unfortunately, the duration of the 
immunity conferred by these two vaccines is not lifelong (9). 
Moreover, recent data indicated that protection from aP vaccines 
wears off faster than that induced by wPs. This weakness in the 
current vaccines together with the lack of optimal vaccination 
coverage and the evolution of the causal agent to greater vaccina-
tion resistance have contributed to the recent rise in pertussis 
incidence and fatalities (10–12). While coverage is improved and 
better vaccines are designed, many countries have added vaccina-
tion boosters beyond the primary doses with the main aim at 
reducing both the disease burden and the incidence in the most 
vulnerable populations.
Maternal pertussis immunization during the third trimester of 
every pregnancy is one of the recent strategies recommended in 
several countries to improve pertussis control in infants (13, 14). 
The reported safety of the acellular vaccine when used during 
pregnancy and the placental transfer of pertussis antibodies from 
mothers to their infants that has been detected argue in favor of 
this strategy (15–17). Nevertheless, the question of whether or 
not this approach is able to effectively protect neonates against 
pertussis and how the transmitted maternal immunity affects 
the protection conferred by subsequent infant vaccination are 
still insufficiently clear. Recently, Amirthalingam et al. reported 
the effectiveness of maternal immunization in preventing infant 
pertussis, as evaluated 1  year after the introduction of the 
maternal-pertussis-immunization program in England in 2012 
(18). Moreover, in the 3 years following its introduction vaccine 
effectiveness against confirmed pertussis has been sustained 
>90% with a vaccine effectiveness against infant deaths esti-
mated at 95% (95% confidence interval, 79–100%). Furthermore, 
the authors reported that the protection conferred by maternal 
immunization was retained in infants who received the first dose 
of the primary series (18). Though all these data are highly prom-
ising and support the successfulness of maternal immunization, 
the reported number of cases in that study was, unfortunately, 
small; and therefore an ongoing assessment is still needed.
The use of animal models has also indicated an effective pro-
tection against pertussis in the offspring of mothers immunized 
during pregnancy. In a primate model (baboons), it was observed 
that both maternal and neonatal vaccinations were found to 
confer protection against the pathogen (19). The authors of those 
baboon experiments suggested that the transmitted maternal 
antibodies alone would be sufficient to confer protection against 
pertussis symptoms. In pigs, protection seems to be related to the 
presence of anti-B. pertussis antibodies in the colostrum (20, 21). 
We need to emphasize here that although in mice a protection 
transmitted to the pups via the placenta has been duly demon-
strated, a transmission via the breast milk cannot be discarded 
since that via has not yet been completely investigated. Oda et al. 
(22) and Quinello et al. (23) reported some data on that topic.
We thus used this mouse model in order to substantially 
enhance our understanding of the efficacy of maternal pertussis 
immunization in the protection of subsequent offspring as well 
as determine the potential interference of maternal immunity 
with the eventual protection of those offspring by the primary 
vaccination against B. pertussis.
MaTerials anD MeThODs
Mice
BALB/c mice (4 weeks old), obtained from the Instituto Biológico 
Argentino SAIC (Biol Argentina), were kept in ventilated cages 
and housed under standardized conditions with regulated day-
light, humidity, and temperature. The animals received food and 
water ad libitum. Day 1 of gestation was determined when vaginal 
plugs were observed. Breeding cages were checked daily for new 
births, and the pups were kept with their mothers until weaning 
at the age of 4 weeks. The animal experiments were authorized 
by the Ethical Committee for Animal Experiments of the Faculty 
of Science at La Plata National University (approval number 
004-06-15 and 003-06-15).
B. pertussis strain and growth conditions
Bordetella pertussis Tohama phase I strain CIP 8132 was used 
throughout this study as the strain for challenge in the murine 
model of protection. B. pertussis was grown in Bordet–Gengou 
agar supplemented with 15% (v/v) defibrinated sheep blood 
(BG-blood agar) for 72 h at 36.5°C. Isolated colonies were replated 
in the same medium for 24 h and then resuspended in phosphate-
buffered saline (PBS: 123 mM NaCl, 22.2 mM Na2HPO4, 5.6 mM 
KH2PO4 in MilliQ® nanopure water; pH 7.4). The optical density 
(OD) at 650 nm was measured and serial 10-fold dilutions plated 
onto BG-blood agar to determine the density of the challenge 
inoculum.
Vaccines
The maternal immunization protocols were performed with the 
three-valent pertussis aP BOOSTRIX® (GSK, GlaxoSmithKline), 
with composition per human dose (HD): pertussis toxoid (8 µg), 
pertactin (2.5  µg), filamentous hemagglutinin (8  µg), tetanic 
toxoid (20 IU), and diphtheria toxoid (2 IU). For all experiments, 
immunization was carried out through the use of a 1/10 HD of 
that vaccine, hereafter referred to as a mouse dose (MD). The 
vaccinations of infant mice were performed with 1 MD of the 
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aP, a commercial wP vaccine (DTP vaccine, PT. BIO FARMA, 
Indonesia), or the B. pertussis-outer-membrane-vesicle-based 
vaccine formulated by us as previously described (24), to be 
referred to as the OMV vaccine.
experimental Protocol
Maternal Immunization and Offspring Protection
Female BALB/c mice (n = 10) were intraperitoneally immunized 
with three doses of commercial acellular vaccine (aP) Boostrix™ 
1/10 HD at days 0 and 14. Before applying the third vaccine, dose 
females were housed with males within the same cage and daily 
checked for pregnancy, when mucosal vaginal plug was detected a 
third vaccine dose was applied. Pregnancy eventually occurs after 
detection of vaginal mucosal plug. Mice couples stayed cohoused 
until the end of the experiment. Non-immunized mice were used 
as negative control of protection. Offspring born to either immu-
nized or non-immunized mothers were intranasally challenged 
with a sublethal dose (106–108 CFU 40 µl−1) of B. pertussis Tohama 
phase I at 21 days of life. Seven days after challenge, mice were 
sacrificed, and their lungs were harvested, homogenized in PBS 
and plated in serial dilutions onto BG-blood agar to count CFUs 
after incubation at 37°C for 3–4 days. At least three independent 
assays were performed.
Passive Immunization through Lactation
To investigate the protection of infant mice by means of pas-
sive immune transfer through lactation; after giving birth, 
aP-vaccinated mothers were separated from their own pups and 
exchanged with non-immunized mothers that had given birth at 
the same time. The changeling pups were then breast-fed by the 
surrogate mothers until weaning at the age of 4 weeks. Finally, the 
mice were infected with B. pertussis and protection assessed on 
day 7 as described above.
Adoptive Transfer
To study protection conferred by passive transfer, pooled serum 
(100  µl) or spleen cells (20–50  ×  106) from mice born from 
non-immunized or immunized dams were transferred intraperi-
toneally to 4-week-old naïve mice. Twenty-four hours later, the 
mice were infected with B. pertussis and protection assessed on 
day 7 as described above.
Effect of Infant Vaccination on Protection  
in Mice Born to Vaccinated Mothers
To study the effect of active immunization of infant mice born to 
vaccinated mothers on protection from subsequent pertussis infec-
tion, the offspring were immunized at 4 weeks of age with an MD 
of the commercial aP, a commercial wP vaccine, or with the OMV 
vaccine. Non-immunized offspring from aP-immunized mothers 
or aP-immunized mice at 4 weeks of age were used as controls. 
Mice were challenged with B. pertussis 2 weeks after receiving the 
vaccine dose and protection assessed on day 7 as described above.
enzyme-linked immunosorbent assay
As we previously described (25), plates (Nunc A/S, Roskilde, 
Denmark) were coated with sonicated B. pertussis Tohama 
phase I (whole-cell lysates), designated Bp, or with the purified 
recombinant pertussis toxin (PTxA), each at 3 µg/ml in 0.5 M 
carbonate buffer pH 9.5, by means of an overnight incubation at 
4°C. The rinsed plates were then blocked with 3% milk in PBS 
(2 h 37°C) and incubated with serially diluted samples of mouse 
serum (1 h 37°C). In the experiments described above, the sam-
ples of blood used were collected from mothers at delivery, from 
mothers and pups at weaning, from mothers and pups before 
pup challenge, and from pups 13 days after immunization. The 
sera were obtained after leaving the blood samples to clot for 1 h 
at 37°C followed by centrifuging for 10 min at 7,000 × g. IgGs 
from individual serum or pooled sera bound to the plates were 
detected after a 2-h incubation with goat anti-mouse-IgG-linked 
horseradish peroxidase (1:8,000 Invitrogen, USA). As substrate 
1.0  mg/ml o-phenylenediamine (Bio Basic Canada, Inc.) in 
0.1 M citrate-phosphate buffer, pH 5.0 containing 0.1% hydrogen 
peroxide was used. ODs were measured with Titertek Multiskan 
Model 340 microplate reader (ICN, USA) at 492 nm, and the OD 
was plotted as a function of the log of the (serum dilution)−1. 
A successful assay produced for each antibody sample a sigmoidal 
curve in this type of plot. The titer of each antibody sample was 
determined from this curve by identifying by GraphPad Prism® 
software the concentration (expressed as inverse of the dilution of 
the antibody) that provokes a half way between the basal response 
and the maximal response.
Of the experimental protocol—it performed in triplicate—one 
representative experiment is presented in Section “Results.”
statistical analysis
The data were evaluated statistically by one-way analysis of vari-
ance followed by the Tukey test post hoc (via the GraphPad Prism® 
software). Differences were considered significant at a p < 0.05.
resUlTs
Maternal immunization and Protection  
of the Offspring against B. pertussis 
infection
To evaluate the protection of the offspring against B. pertussis 
infection through a maternal-vaccine-induced immunization, 
female mice were vaccinated twice with a commercial aP within 
an interval of 2 weeks, then mated with male mice and a third 
aP-vaccine dose administered when a vaginal plug was detected. 
Non-immunized females were mated with male mice at the same 
time to serve as the negative-control dams. Mice born to aP-
immunized (hereafter referred to as Ipups) or non-immunized 
females (hereafter referred to as Cpups, for negative control) 
were challenged (intranasally) with 106 CFUs of B. pertussis at 
4 and 16 weeks after birth (Figure 1A). We observed significant 
differences in the lung B. pertussis bacterial counts between mice 
born to immunized mothers and the negative-control group 
(Figure 1B; p < 0.001). Differences in CFUs of six to seven orders 
of magnitude were detected between the Ipups and the Cpups 
challenged at 4 weeks after birth and of about four to five orders 
of magnitude after challenge at 16 weeks of age. Once again, the 
CFU counts in the Ipups were non-detectable. What is notable, 
FigUre 1 | Effect of maternal immunization on protection of offspring against Bordetella pertussis infection. (a) Schematic representation of the maternal 
vaccination and challenge protocols. Female mice were vaccinated twice with a commercial acellular pertussis (aP) at a 2-week interval; mated with male mice;  
and when the vaginal plug was detected, a third aP dose was administered. Non-immunized females were mated with male mice at the same time as the 
immunized females. Mice were born 3–4 weeks after the last immunization. Mice born to aP-immunized or non-immunized females (controls) were challenged with 
B. pertussis at 4 and 16 weeks after birth. Mothers and pups were bled at different time points as indicated by the dotted vertical arrows. (B) Short- and long-term 
protection of offspring through maternal immunization. Mice born to aP-immunized (Ipups n = 6, black bars) or non-mmunized (Cpups n = 6, white bars) females 
were challenged with B. pertussis Tohama I at 4 and 16 weeks after birth. The number of bacteria recovered from mouse lungs, expressed as the log10 of CFUs per 
lungs, is plotted on the ordinate for the times after birth in weeks indicated on the abscissa, with the data representing the means ± the SD. The dotted horizontal 
line indicates the lower limit of detection. *p < 0.001 Ipups versus Cpups. (c) The anti-whole-cell-B. pertussis (a-Bp)- and anti-pertussis toxin (a-PTxA)-specific IgG 
titers were determined in the mother and in the offspring at the indicated time points. The titers are expressed as the geometric mean of the data from each group. 
p < 0.001 a-PTxA and a-Bp IgG titers in Ipups at 4 weeks after birth versus those detected at 16 weeks after birth. The results from one representative experiment 
are shown. nd, not detected.
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however, is that the difference found at 16 weeks after birth was not 
as high as after 4 weeks after birth (four to five versus six to seven 
orders of magnitude) probably because of the age of mice since at 
16 weeks mice seem to be less susceptible to pertussis infection 
(Figure 1B; cf. CFUs recovered from Cpups at 4 versus 16 weeks 
of age). As to the antibody titers, we performed a quantification 
of both the anti-whole-cell-B. pertussis (a-Bp) and the anti-PTxA 
(a-PTxA) antibodies in the mothers and in the offspring at the 
times indicated in Figures  1A,C lists the a-Bp- and a-PTxA-
antibody titers detected in the immunized mothers and in their 
offspring. In contrast to the undetectable titers in the Cpups born 
to non-immunized females, significant levels of a-Bp and a-PTxA 
IgGs were present in the serum of the Ipups (Figure  1C). The 
antibody titers in the Ipups were lower at 16 weeks than at 4 weeks 
after birth, although the titers were still high enough to afford 
complete protection against B. pertussis infection (Figure  1B). 
With respect to the time elapsed between the administration 
of the last dose of vaccine to the mother and the evaluation of 
the protective capacity in the offspring, it is important to point 
out that the immunity transferred to the offspring still provided 
protection against B. pertussis infection even for the pups born to 
mothers whose last vaccination was given at up to 5 weeks before 
pregnancy (Table 1).
Another significant result observed in relation to maternal 
vaccination and immune protection of the successive litters was 
that the immunity acquired during the first pregnancy proved to 
be capable of conferring protection to the offspring born in later 
pregnancies (Figures 2A,B). For example, we detected a protec-
tion against B. pertussis infection in the Ipups born in the second 
pregnancy in which the reduction in CFUs recovered from the 
lungs was by more than six orders of magnitude below the levels 
determined in the Cpups (Figure 2B). Moreover, we also detected 
differences of 3.9–5.2 orders of magnitude between the CFUs 
recovered in the Ipups born in the third through the fifth pregnan-
cies and those measured in the Cpups (Figure 2B). Of particular 
interest to us was that the antibody titers against PTxA detected 
in the pups born in the later pregnancies were lower than those 
recovered from the pups born in the earlier ones; but nevertheless, 
as we observed here, those titers were still high enough to protect 
the pups against B. pertussis infection (Figure 2B). In this sense, 
the technique produced a degree of redundancy of protection that 
constitutes a benefit in this model system simulating a clinical 
situation in generating a certain margin of error that would be of 
pragmatic value in the latter circumstance.
Donor Pups for examination of effector 
Mechanisms of Passive immunity Transfer
To evaluate the contribution to protection of the transferred 
maternal antibodies, we performed transfer experiments of 
immune sera from Ipups to naïve mice. As a negative control of 
this protection, an equal volume of non-immune sera (100  µl) 
from Cpups was transferred to groups of five of those naïve female 
TaBle 1 | Protection of offspring through maternal immunization before 
pregnancy.
log10cFU/lungs
Time elapsed between the last immunization and 
pregnancy
0 weeks 1 week 2 weeks 5 weeks
Cpups 7.00 ± 0.86 7.52 ± 0.42 7.12 ± 0.54 7.72 ± 0.64
Ipups 1 ± 0.0 1 ± 0.0 1.07 ± 0.15 1 ± 0.0
p < 0.001 Ipups versus Cpups at each tested time.
FigUre 2 | Duration of protective immunity conferred by maternal immunization beyond the first pregnancy. (a) Schematic representation of the maternal 
vaccination and pup-challenge protocol. Female mice were vaccinated twice with commercial acellular pertussis (aP) at a 2-week interval; mated with male mice; 
and when the vaginal plug was detected, a third aP dose was administered. Non-immunized females were mated with male mice at the same time as the 
immunized females. The first birth was 3–4 weeks after the last immunization. Successive births occurred at intervals of 5–8 weeks. Mice born to aP-immunized or 
non-immunized females (the negative controls) were challenged with Bordetella pertussis at 4 weeks after birth. Mothers and pups were bled 1 day before pup 
challenge as indicated by the dotted vertical arrows. (B) Protection conferred to the offspring born in later pregnancies by maternal immunity acquired during the 
first pregnancy. Mice born to aP-immunized (Ipups n = 5) or non-immunized (Cpups n = 5) females were challenged with B. pertussis Tohama I 4 weeks after birth. 
The protection conferred to the offspring through maternal immunization during the first pregnancy was estimated by determining the number of bacteria recovered 
from mouse lungs. The bacterial counts expressed as the log10 of CFU per lungs, is plotted on the ordinate as a function of the number of births after the initial 
delivery indicated on the abscissa. *p < 0.001 Ipups versus Cpups. The anti-pertussis toxin (a-PTxA) IgG titers in the mothers and the offspring determined at the 
time of challenge are listed below the abscissa. The titers are expressed as the geometric mean of the data from each group (n = 5). p < 0.001 a-PTxA IgG titers in 
Ipups from the first and second deliveries versus those detected in Ipups from the third through the fifth deliveries. The results from one representative experiment 
are presented.
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BALB/c mice. Twenty-four hours after transfer, all the mice were 
infected with a sublethal dose of B. pertussis and sacrificed 7 days 
later to determine the number of CFUs in the lungs. Transfer of 
100 µl of sera from Ipups either with high titer (sera from pups 
from the first and second deliveries, the earlier pregnancies) or 
with low titer (sera from pups born from the third through the 
fifth deliveries, the later pregnancies) was found to confer pro-
tection (Figure 3). A reduction of 2.76 logs or 1.17 logs in CFU 
counts was detected relative to the control group (Figure 3) in 
the mice thus passively immunized with a high and a low titer of 
immune sera, respectively (p < 0.05).
Similar transfer experiments were also performed with spleen 
cells removed surgically from Ipups born from the earlier deliver-
ies and injected into naïve mice, with the spleen cells from non-
immunized mice being used as a negative control for protection. 
One day after the transfer, the recipient mice were challenged with 
B. pertussis, and 7 days after the challenge the CFUs in the lungs 
FigUre 4 | Effect of passive immunization through spleen cells collected 
from Ipups on protection from infection. Whole spleen cells (20–50 × 106) 
from Ipups or Cpups (controls) were tested as possible vehicles of immune 
protection by passive transfer to naïve mice. Twenty-four hours after transfer, 
the mice were infected with Bordetella pertussis and sacrificed 7 days later to 
determine the CFUs in the lungs. Ipup-recipients were used as a positive 
control. In the figure, the number of bacteria recovered from the mouse 
lungs, expressed as the log10(mean CFUs ± SD of per lungs), is plotted on 
the ordinate for each of the spleen-cell-recipient groups (n = 7) indicated on 
the abscissa. The dotted horizontal line marks the lower limit of detection. 
*p < 0.05 Ipups versus both spleen-cell recipient groups.
FigUre 3 | Effect of passive immunization on protection through sera 
collected from Ipups. Pooled sera from either early pregnancy Ipups with high 
anti-pertussis toxin (a-PTxA) titer or late-pregnancy Ipups with low a-PTxA 
titer were tested by transfer to naive (Cpup n = 5) female mice. Pooled sera 
from Cpups transferred to naive female mice were used as negative control 
of protection. Twenty-four hours after transfer, the mice were infected with 
Bordetella pertussis and sacrificed 7 days later to determine the CFUs in the 
lungs. In the figure, the number of bacteria recovered from mouse lungs, 
expressed as the log10 of CFUs per lungs, is plotted on the ordinate for each 
of the two serum-donor groups (early- and late-pregnancies) indicated above 
the bars. *p < 0.05 Ipup serum versus Cpup serum. The IgG a-PTxA titers 
are listed for each pool below the abscissa (nd, not detected).
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of the recipients were counted. In this instance, no significant 
difference was found between the control group and the group 
injected with spleen cells from the Ipups (Figure 4).
Passive immunization through lactation
We also evaluated passive immunization through lactation. To 
achieve this aim, pups born to immune mothers (Ipups) were 
fostered to non-immune mothers (Ipups–Cmother), and pups 
born from control mothers were fostered to immune mothers 
(Cpups–Imother). Ipups breast-fed by their immune mother 
(Ipups–Imother) and Cpups breast-fed by their non-immune 
mother (Cpups–Cmother) were used as the respective positive and 
negative controls. After all the pups were suckled for 21 days, the 
pups’ sera were collected to analyze the titers of a-PTxA and a-Bp 
IgGs before B. pertussis challenge. Pups were then challenged with 
a sublethal dose of B. pertussis to analyze the protection against 
infection. Through this experimental protocol and the resulting 
assays, we detected that pups from the Ipups–Imother and Cpups–
Imother groups exhibited high titers of a-PTxA and a-Bp IgGs 
(Figure 5A) and also possessed a high degree of protection against 
B. pertussis—i.e., a reduction in the CFUs recovered from the lungs 
by more than six orders of magnitude (Figure 5B). In contrast, pups 
from the group Ipups–Cmother contained low titers of a-PTxA and 
a-Bp IgGs and retained a low degree of protection. The lowest titers 
of a-PTxA and a-Bp IgGs and degrees of protection were detected 
in the pups from the Cpups–Cmother group (Figures 5A,B).
effect of infant Vaccination in Mice Born 
to aP-Vaccinated Mothers on Protection
To evaluate the possible interference of maternal immunization 
with subsequent infant immune boosting, offspring born to 
aP-vaccinated mothers, upon weaning from their mothers, were 
split into four groups at 4 weeks after birth. Three groups were 
treated with a single dose of either the aP vaccine, a commercial 
wP vaccine, or the OMV vaccine (Figure 6A), while the remain-
ing group was left untreated. Cpups that received one dose of 
the aP vaccine at 4 weeks after birth were also used as control. 
Two weeks after vaccination of the infant mice, the antibody 
titers to PTxA were measured. We observed that the titers in 
aP-vaccinated Cpups (given a single dose) were slightly higher 
than those detected in the non-vaccinated Cpups. In the mice 
born to aP-vaccinated mothers (i.e., the vaccinated Ipups), the 
titers detected after vaccination with any of the three vaccines 
tested were lower than those quantified in Ipups left untreated 
(blunting effect) (Figure  6B). Moreover, that the titers in the 
non-vaccinated Ipups were higher than those detected in the 
vaccinated Cpups was most notable (Figure  6B). All the mice 
in this experiment, including the Cpups used as the negative con-
trol for protection, were then challenged with 106–107 CFUs of 
B. pertussis 2 weeks after the postnatal immunization of the Ipups. 
We observed that at 7 days after challenge, the vaccinated Cpups 
exhibited a reduced bacterial burden in the lungs by 1.5 logs 
(32-fold) compared with the non-vaccinated Cpups (Figure 6C). 
Furthermore, aP vaccination of the infant mice born to vacci-
nated mothers did not interfere with the maternally transmitted 
protective immunity, as evidenced by a comparable reduction in 
the CFUs detected in the lungs of approximately 5 logs compared 
with the burden of the non-vaccinated Cpups. In these experi-
ments, we also observed that the immunization of Ipups with 
vaccines of different antigenic compositions from that used in 
FigUre 5 | Effect of passive immunization through lactation on pertussis protection. Pups born from immune mothers (Ipups) were fostered to non-immune 
mothers (Ipups–Cmother), and pups born from control mothers were fostered to immune mothers (Cpups–Imother). Ipups breast-fed by their immune mother 
(Ipups–Imother) and Cpups breast-fed by their non-immune mother (Cpups–Cmother) were used as the respective positive and negative controls. All the pups 
(n = 6 for each group) were suckled for 21 days. (a) Sera from mothers and pups were collected at different time points to analyze the titers of anti-pertussis toxin 
(a-PTxA) and anti-whole-cell-B. pertussis (a-Bp) IgGs. The titers are expressed as the geometric mean of the data for each group (n = 6). (B) Pups were challenged 
with a sublethal dose of Bordetella pertussis Tohama phase I to analyze protection. In the figure, the number of bacteria recovered from the mouse lungs, expressed 
as the log10(mean CFUs ± SD of per lungs), is plotted on the ordinate for each of the dam-suckling groups indicated on the abscissa. The dotted horizontal line 
marks the lower limit of detection. Two independent experiments were performed. *p < 0.05 for Ipups–Imother and Cpups–Imother versus the other groups and for 
Ipups–Cmother versus Cpups–Cmother.
FigUre 6 | Effect of heterologous mother–pup vaccination on protection against Bordetella pertussis challenge. (a) Schematic representation of vaccination and 
challenge protocols. Female mice were immunized with three doses of commercial aP vaccine on days 0 and 14; mated with male mice; and when the vaginal plug 
was detected, a third aP dose was administered. Four weeks after birth, the offspring received either no vaccine (n = 8) or one dose of the aP, OMV, or wP vaccine 
(n = 8 in each group), as indicated below the abscissas of panels (B,c). Two weeks later, the pups were challenged with B. pertussis and the bacterial burden in the 
lungs measured 7 days after challenge. Pups born to vaccinated or non-vaccinated mothers and receiving no postnatal vaccine served as controls. The pups (n = 5 
for each group) were bled and the anti-pertussis toxin (a-PTxA) IgG titers determined 1 day before the challenge as designated by the dotted vertical arrow.  
(B) The titers, plotted on the ordinate, are expressed as the geometric mean of the data from each group specified on the abscissa. *p < 0.05 pups born to 
immunized mother versus others groups, and the nd signifies not detected. (c) In the figure, the number of bacteria recovered from the mouse lungs, expressed as 
the log10(mean CFUs ± SD per lung), is plotted on the ordinate for each group indicated on the abscissa. *p < 0.05 for negative control versus other groups, and 
aP-immunized pups born to non-immunized mother versus others groups. The dotted horizontal line marks the lower limit of detection. Of the three independent 
experiments that were performed, the results from a single representative one is presented.
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the maternal immunization reciprocally did not interfere with the 
maternally transmitted protective immunity since after postnatal 
vaccination with either a commercial cellular vaccine (wP) or our 
previously designed OMV vaccine the protection conferred was 
similar to that seen in infant mice born to aP-vaccinated mothers 
with or without postnatal aP vaccination (Figure 6C).
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DiscUssiOn
The vaccination of women with aP during pregnancy is expected 
to provide infants with a certain degree of protection from 
pertussis until they are old enough to be vaccinated themselves. 
Because of this strategy and the data reported on its safety, the 
Advisory Committee on Immunization Practices (ACIP) recom-
mended in 2011 that unvaccinated pregnant women receive a 
dose of tetanus toxoid, reduced diphtheria toxoid, and aP vac-
cine (26). In an effort to reduce the pertussis burden in infants, 
in 2012, the ACIP recommended the use of aP during every 
pregnancy (27). In their publication of August 2015, the WHO 
stated that they considered the vaccination of pregnant women 
to be most likely the greatest cost-effective additional strategy 
for preventing disease in infants too young to be vaccinated, 
with that approach appearing to be more effective and favorable 
than the so-called cocooning tactic, the vaccination of adults 
in close contact with infants (6). Indeed, WHO recommended 
that the national programs might consider the vaccination of 
pregnant women with one dose of aP administered during the 
second or third trimester or at least 15 days before delivery as a 
control strategy in addition to routine primary infant pertussis 
vaccination either in entire countries, or in other more limited 
settings having a high or increasing infant morbidity and/or 
mortality from the disease. Although the present time is still 
early to assess the definitive effect of implementing this strategy 
on the disease in infants, reports in support of that approach 
have already appeared in the literature (28, 29). In particular, 
several studies evidenced the placental transfer of anti- 
B. pertussis antibodies from aP-vaccinated mothers to their 
infants where the infants born to those immunized mothers had 
a high level of antibodies during their first months of life (28, 29). 
A further report in England related the key observation that 
vaccine effectiveness against laboratory-confirmed pertussis 
had been sustained during the 3  years following the vaccine’s 
introduction in 2012 (18). Also highly significant was the finding 
that the disease incidence in infants less than 3 months of age had 
remained low despite a high persistence in those aged 1 year and 
older (18). In 2017, a retrospective cohort study appeared that was 
designed to evaluate whether or not pertussis-infected infants 
born from 2011 through 2015 whose mothers had received aP 
vaccine during pregnancy had less severe pertussis than infants 
born to unvaccinated mothers. The authors concluded that the 
infants with pertussis whose mothers had been aP-vaccinated 
during pregnancy had a significantly lower risk of hospitalization 
and admission to intensive-care units as well as shorter hospital 
stays (30). Another promising aspect found in the Amirthalingam 
et  al. (18) study was that additional protection from maternal 
immunization was retained in infants who subsequently received 
their first dose in the primary Amirthalingam series (18).
Animal models had been used earlier to obtain information 
about that strategy. Although the data reported once again had 
been scarce, evidence was nevertheless garnered for protection by 
the aP vaccine when used during pregnancy against intracerebral 
infections of B. pertussis and those contagions transmitted by 
aerosols to infant mice (22). In those studies, mice of from 6 to 
10  days of age born to aP-immunized mothers were protected 
against an aerosol challenge with B. pertussis strain 18323. The 
authors ascertained that the protection was transferred from the 
dams to their offspring first through the placenta and then through 
the milk (22). More recently, Feunou et al. (31) confirmed that 
maternal immunization protected the offspring against B. pertussis 
challenge; but in their experimental paradigm, the protection 
waned and was eventually lost after the postnatal vaccination of 
the infant mice with the selfsame vaccine (31).
In the experiments reported here, we used just such a mouse 
model to enhance our understanding of that specific form of 
maternal immunization. In agreement with previous reports, 
we detected that maternal immunization with an aP vaccine—in 
our paradigm, administered in three doses (one being during 
the pregnancy)—led to offspring protection against B. pertussis 
infection (Figure 1). Moreover, we confirmed that the antibody 
levels to B. pertussis and PTxA were accordingly higher in those 
neonates (the Ipups) than in mice born to non-immunized 
females (the Cpups). The antibody titers in the offspring declined 
at 16 weeks relative to the levels at 4 weeks after birth, although 
the titers were high enough to protect the neonates against 
B. pertussis infection. Furthermore, the transferred antibodies, 
but not the spleen cells, from Ipups to naïve mice were sufficient 
to confer protection (Figure 3).
What was interesting to us was the observation that the immu-
nity transferred to the offspring had a protective capacity even 
for pups born to mothers whose last dose of vaccine was given 
some weeks before pregnancy. Moreover, we detected that the 
immunity acquired during the first pregnancy was even capable 
of conferring protection to the offspring born in later pregnan-
cies. We noted that although the titers of antibodies against PTxA 
were low, protection against pertussis in the Ipups born in those 
later deliveries was still significantly elevated (Figure 2B). These 
results, though having been obtained in a murine model, would 
underscore the need to revise the frequency with which human 
maternal immunization should be conducted.
In agreement with Oda et al. (22), we detected that the main 
protection was transferred through colostrum and/or milk. Those 
authors found that challenged infant mice born to mothers immu-
nized with either the aP or the wP vaccine twice before mating 
evidenced the lowest increase in the number of CFUs per lung. 
Moreover, out of eight mice, seven deaths were registered in the 
non-immunized group, whereas five deaths occurred in the trans-
placentally immunized group, but only two in the transcolostrally 
immunized mice (22). In our protocol involving a schedule that 
included the administration of a third aP dose during pregnancy, 
we detected high degree of protection against B. pertussis through 
lactation (Figure 5B). In particular, we detected that the Ipups–
Imother and Cpups–Imother experimental groups exhibited high 
a-PTxA and a-B. pertussis IgG titers (Figure 5A) in combination 
with high resulting protection against B. pertussis infection (more 
than a 6-log reduction in the CFUs recovered from the lungs: cf. 
Figure 5B). The results obtained by Quinello et al., in agreement 
with ours, demonstrated that the pertussis-absorbed serum and 
the colostrum pools protected only 30% of the immunized mice, 
whereas purified IgGs protected some 65% (23). Although IgA 
was not measured in this study or in our work, its presence could 
contribute at least in part to protection. In fact, it was reported 
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that IgA induced by oral or nasally delivered pertussis antigens 
formulated with mucosal adjuvants confers protection although 
at levels not so high than the equivalent parenterally delivered 
vaccines [reviewed in Ref. (32)].
Although the data garnered from our murine model under-
scored the significance of breastfeeding in protecting infants 
against pertussis infection, we must point out that this protection 
could be less substantial in humans since in Homo sapiens the 
majority of the maternal IgG is transferred to the fetus in utero 
during pregnancy (33) and not via the milk.
We also observed that, when infant mice born to aP-immu-
nized mothers (the Ipups) were vaccinated at 3 weeks of age with 
the same aP vaccine or a different one (i.e., a commercial wP 
or the OMV vaccine); the titer of IgG against a-PTx decreased 
(Figure  6B), but the maternally derived protection was not 
reduced upon that subsequent vaccination, regardless of the type 
of vaccine administered. These results seem to be contradictory 
in principle to those reported by Feunou et al., but we must bear 
in mind that those authors applied two vaccine boosters, one at 
7 days and another at 3 weeks of life (31). The blunting effect on 
protection that the authors observed could have resulted from 
the application of those boosters—and particularly the ones per-
formed during neonatal life—at a time when the antibody titers in 
the pups were still high. In contrast, our results are in agreement 
with those observed in humans in whom the protective capacity 
conferred by maternal immunization was retained in neonates 
receiving their first dose of the primary series (18).
Though the use of mouse models to research maternal vacci-
nation is not expected to completely replicate human physiology, 
the results obtained with a model of this design will enable a test 
of the proposed hypotheses under controlled conditions, where 
the forthcoming results can then refine those hypotheses for fur-
ther validation in subsequent human studies. Here, in the present 
mouse model, we have demonstrated that immunization with aP 
during pregnancy or up to 5 weeks prior effectively protects new-
borns against pertussis. Although the titer of maternal antibodies 
in the infant offspring diminishes with time, protection is not 
reduced for at least up until 4 months of age. Moreover, subse-
quent vaccination of the infant mice with the same vaccine or a 
different one from the type used during pregnancy did not affect 
the transferred maternal protection (Figure  6). The potential 
blunting of protection conferred by maternal immunization 
through infant vaccination could be developed depending on the 
antibody levels in the infants. Another important finding here 
described was that maternal-vaccination-acquired immunity 
from the first pregnancy still conferred protection to offspring up 
to the fourth pregnancy. The results presented here reinforce the 
need to continue studying that blunting effect in humans as well 
as to revise the frequency of vaccination in successive pregnancies 
according to the time between each one.
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